China Glioblastoma Multiforme Treatment Market Size & Outlook
Related Markets
China glioblastoma multiforme treatment market highlights
- The China glioblastoma multiforme treatment market generated a revenue of USD 251.1 million in 2025 and is expected to reach USD 562.8 million by 2033.
- The China market is expected to grow at a CAGR of 10.6% from 2026 to 2033.
- In terms of segment, surgery was the largest revenue generating treatment in 2025.
- Tumor Treating Field (TTF) Therapy is the most lucrative treatment segment registering the fastest growth during the forecast period.
Glioblastoma multiforme treatment market data book summary
| Market revenue in 2025 | USD 251.1 million |
| Market revenue in 2033 | USD 562.8 million |
| Growth rate | 10.6% (CAGR from 2026 to 2033) |
| Largest segment | Surgery |
| Fastest growing segment | Tumor Treating Field (TTF) Therapy |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy (Bevacizumab), Tumor Treating Field (TTF) Therapy |
| Key market players worldwide | Merck & Co Inc, Amgen Inc, Roche, Pfizer Inc, Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries, Arbor Pharmaceuticals, Amneal Pharmaceuticals, Karyopharm Therapeutics Inc, Sumitomo Dainippon Pharma Oncology |
Other key industry trends
- In terms of revenue, China accounted for 6.2% of the global glioblastoma multiforme treatment market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Asia Pacific, China glioblastoma multiforme treatment market is projected to lead the regional market in terms of revenue in 2033.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 353.3 million by 2033.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Glioblastoma Multiforme Treatment Market Scope
Glioblastoma Multiforme Treatment Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Sumitomo Dainippon Pharma Oncology | View profile | 251-500 | Cambridge, Massachusetts, United States, North America | https://www.sdponcology.com/ |
| Amneal Pharmaceuticals | View profile | 5001-10000 | Bridgewater, New Jersey, United States, North America | http://amneal.com/ |
| Arbor Pharmaceuticals | View profile | 501-1000 | Atlanta, Georgia, United States, North America | http://www.arborpharma.com |
| Karyopharm Therapeutics Inc | View profile | 325 | 85 Wells Avenue, 2nd Floor, Newton, MA, United States, 02459 | https://www.karyopharm.com |
| Roche | View profile | 10001+ | Basel, Basel-Stadt, Switzerland, Europe | http://www.roche.com |
| Sun Pharmaceutical Industries | View profile | 10001+ | Mumbai, Maharashtra, India, Asia | http://www.sunpharma.com |
| Merck & Co Inc | View profile | 72000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | https://www.merck.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
| Amgen Inc | View profile | 26700 | One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799 | https://www.amgen.com |
| Teva Pharmaceutical Industries Ltd | View profile | 37851 | 124 Dvora HaNevi’a Street, Tel Aviv, Israel, 6944020 | https://www.tevapharm.com |
China glioblastoma multiforme treatment market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to glioblastoma multiforme treatment market will help companies and investors design strategic landscapes.
Surgery was the largest segment with a revenue share of 42.97% in 2025. Horizon Databook has segmented the China glioblastoma multiforme treatment market based on surgery, radiation therapy, chemotherapy, targeted therapy (bevacizumab), tumor treating field (ttf) therapy covering the revenue growth of each sub-segment from 2021 to 2033.
The Chinese government offers advanced infrastructure facilities to foreign investors. In addition, easy availability of cheap labor contributes to the expansion of market players in this country. The focus of major market players on China is likely to aid market growth over the forecast period. Increasing initiatives undertaken by market players to develop new treatment options for brain cancer are expected to propel the market growth in the country.
In 2018, GBM accounted for 17% of newly diagnosed brain and nervous system cancers in China, as reported by WHO. I-Mab, a Chinese company, is developing a novel long-acting recombinant human interleukin-7 (rhIL-7), for GBM treatment in China. Moreover, CANbridge Life Sciences’ IND application for a Phase II/III clinical study of lead candidate, CAN008, was approved by China FDA. The clinical trial will evaluate safety and efficacy of weekly CAN008 + re-radiation therapy (rRT) in GBM patients.
Reasons to subscribe to China glioblastoma multiforme treatment market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of China glioblastoma multiforme treatment market databook
-
Our clientele includes a mix of glioblastoma multiforme treatment market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the China glioblastoma multiforme treatment market , including forecasts for subscribers. This country databook contains high-level insights into China glioblastoma multiforme treatment market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Partial client list
China glioblastoma multiforme treatment gbm market size, by treatment, 2021-2033 (US$M)
China Glioblastoma Multiforme Treatment Market Outlook Share, 2025 & 2033 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
